HEALTHQUARTZ
Kailera's oral weight loss pill met its trial goal, but nausea hit 70% of patients
Kailera's oral weight loss pill HRS-7535 met its trial goal in Phase 3, but 70% of patients experienced nausea. The company's stock dropped 10% following the data release.
Related Signal
Adjacent reporting
- Zealand Pharma loses a fifth of its value as many users gave up taking weight-loss drug during trial
- Oral GLP-1 pill delivers nearly 12 percent weight loss in 36 weeks, study finds
- Tired of nausea or taking a GLP-1 pill every day? These experimental drugs could be better than Zepbound and Wegovy.
- Weight loss drug maker sinks 25% after new safety data spooks investors
- Insurance increasingly dropping weight loss drugs like Wegovy, Zepbound
- Definium’s shares surge 55% after LSD-based depression pill delivers strong results